MBI Incubator at Gateway Park
The MBI Incubator at Gateway Park is a joint partnership between the Massachusetts Biomedical Initiatives and WPI—in particular, the Bioengineering Institute. The incubator, located on the ground floor of the newly constructed WPI Life Sciences building, houses laboratories, shared equipment, and offices for up to six start-up biomedical companies. This collaboration will specifically identify and capture academic- and science-related research and transfer these discoveries into commercial company formations and jobs. MBI has built out and operates the facility. MBI has a proven history in promoting the successful statewide economic development strategy of life science business incubation. Further technology growth is also envisioned within the Park as MBI ‘graduate’ incubator companies grow into larger space requirements, thus providing further employment opportunities within our burgeoning Central Massachusetts regional biomedical industry.
Description
The WPI Life Sciences and Bioengineering Center at Gateway Park is the first building phase in the development of a mixed-use life sciences campus on a former Worcester brownfield. The center features new construction to house modern laboratories and support facilities and a renovated former industrial building which provides space for offices, meeting rooms, and other amenities.
Click here to visit the official website of Gateway Park.
Tenants at the Gateway Park Facilities
BioTechnic Products LTD
Contact: Prakash Kadkade, Ph.D., President and CEO
E-mail: pkbiotechnic@aol.com
Phone: 508-755-0646
BioTechnic Products, Ltd. is a privately held biotechnology company focused on the discovery, development and production of naturaceuticals using eco-friendly & sustainable approaches.
Blue Sky Biotech, Inc.
Website: blueskybiotech.com
Contact: Paul Wengender, CEO
E-mail: pwengender@blueskybiotech.com
Phone: 800-363-7795
Blue Sky Biotech, Inc. is a contract research organization providing services in the area of early drug discovery biology R&D. Blue Sky Biotech helps its clients to discover new medicines by providing them with a “one-stop shop” for molecular biology and protein production services.
Informatics and Biocomputing Resources Center
Website: http://www.massbiomed.org/resources.htm
Contact: Joseph Gormley, Managing Director of Informatics and Biocomputing Resources E-mail: jg@massbiomed.org
Phone: 508-797-4200 ext. 203
The Biocomputing Center is an engineering and educational initiative between MBI, industry, and regional academic institutions. The Center acts as a catalyst for collaborative research leading into new computational tools and techniques for the life sciences. Our staff and advisers are computer and life scientists with expertise in laboratory systems, assay development, informatics, biosimulation, and advanced data mining. High potential methods have been developed for commercial and academic partners involved in both basic and applied research. Massachusetts Biomedical Initiatives is committed to accelerating Worcester’s development as a world-class center for biological research. The Biocomputing Center at MBI is a non-profit software engineering and computing facility which contributes to this important scientific and economic development initiative by providing research tool development to companies and organizations throughout the region.
Onnesion, Inc.
Contact: Amit K. Mandal, Ph.D., President
Email: amit.mandal@onnesion.com
Website: : http://www.onnesion.com
Phone: 508-755-7531
Onnesion, Inc. is a privately held chemistry-based company. We conduct research to design and synthesize novel, drug-like molecular scaffolds to assist our customers in biomedical research. We also identify sophisticated molecular scaffolds and building blocks from the literature which we believe can be valuable in drug discovery research, but are not easily accessible in the marketplace. We apply extensive chemistry expertise and cutting-edge chemistry tools to access these molecular structures and make them available to research community at competitive price.
Targeted Cell Therapies, LLC
Website: http://www.targetedcelltherapies.us
Contact: Edward Ginns, M.D., Ph.D., President and CSO
E-mail: eginns@targetedcelltherapies.us
Phone: 508-363-0001
Targeted Cell Therapies (TCT) is an early-stage Massachusetts-based biotechnology company commercializing a powerful technology platform for the oral delivery of therapeutics. Our technology represents a paradigm shift for the delivery of large molecule therapeutics, enabling oral administration and avoiding the need for injection. Formulations consist of ingestible yeast glucan particles containing therapeutic nucleic acid (nanoplexed DNA or RNA) or protein payload molecules that are selectively taken up by intestinal macrophages. The glucan particle payloads are processed by cellular machinery into active therapeutics as the macrophages migrate to sites of inflammation or pathology in tissues throughout the body. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets include low bone density conditions, metastatic bone disease and inflammatory disorders. By combining macrophage targeting with payload versatility, our technology platform has the potential to offer strategic advantages, including improved efficacy and safety, in the delivery of large molecule therapeutics for a broad range of human conditions.
“MBI fosters a unique entrepreneurial and cooperative environment. It also extends support to the tenant companies to be compliant with environmental, health and safety regulations. For a startup company like ours, these supports were extremely valuable to initiate our operation with ease. We were delighted that we have been able to focus on setting up our laboratory and work on other facets of our business from day one.”-Amit K. Mandal, Ph.D., President